| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:2c7c3187068b56f5","evidence_event_ids":["evt_d4f3c42d30b2"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","company":"TransMedics Group, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","article_chars":3324,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_cf4087ac943f1f1c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","content_type":"text/plain","enriched_at":"2026-04-11T06:09:39.907867+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt","source_event_id":"evt_d4f3c42d30b2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"1c20041074fe6a6b","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-10","2026-04-11","May 19, 2026","May 20, 2026","May 6, 2026","December 31, 2026"],"entities":[{"asset_class":"equity","name":"TransMedics Group, Inc.","relevance":"high","symbol":"TMDX","type":"issuer"}],"event_type":"listing","information_gaps":["What changed versus a prior known state is not provided in the signal text (no prior filing comparison content included).","The filing\u2019s full proxy statement details (beyond the overview items listed) are not included in the provided text.","No explicit financial guidance or financial implications are stated in the provided excerpt beyond governance/shareholder vote items."],"key_facts":["Form type: DEFA14A (Schedule 14A proxy statement).","Filed by: TransMedics Group, Inc. (registrant).","Annual meeting: shareholder meeting to be held May 20, 2026.","Meeting time: 8:00 A.M. Eastern Time (virtual meeting noted).","Vote deadline referenced: May 19, 2026, 11:59 PM ET.","Proposal 1: Election of directors (nominees listed as Waleed H. Hassanein, James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Jr., Stephanie Lovell, Merilee Raines, David Weill, M.D.).","Proposal 2: Non-binding advisory approval of compensation paid to named executive officers.","Proposal 3: Amendment to the TransMedics Group, Inc. Amended and Restated 2019 Stock Incentive Plan to increase the maximum aggregate number of shares by 2,750,000 shares and make other changes (as set forth in the proxy statement).","Proposal 4: Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026."],"numeric_claims":[{"label":"shares to increase under 2019 Stock Incentive Plan","value":"2,750,000"}],"primary_claim":"TransMedics Group, Inc. filed Form DEFA14A for its 2026 annual meeting proxy materials, including proposals for director elections, an advisory compensation vote, a stock incentive plan amendment, and auditor ratification.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"TransMedics Group, Inc. filed a Schedule 14A proxy statement (DEFA14A) providing notice of its 2026 annual meeting and summarizing shareholder proposals. The filing includes director election items, an advisory vote on executive compensation, an amendment to the 2019 Stock Incentive Plan, and ratification of the independent auditor.","topics":["SEC filing","proxy statement","annual meeting","shareholder proposals","corporate governance","executive compensation","stock incentive plan","independent auditor"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 TransMedics Group, Inc. \u00b7 Filed 20260410","ticker":"TMDX","tickers":["TMDX"],"title":"TMDX filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1756262/0001193125-26-150360.txt"}}... |